These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25131870)

  • 21. Pemetrexed for treatment of advanced non-small cell lung cancer.
    Fossella FV
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):100-5. PubMed ID: 14981587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
    Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
    Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
    Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
    Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Update of pemetrexed in thoracic oncology].
    Brechot JM; Morère JF
    Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
    Zhang RX; Cai DY; Wu XH; Hua D
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):869-72. PubMed ID: 23291140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
    Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
    Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of Pemetrexed Monotherapy in Advanced Non-Small Cell Lung Cancer Patients with Impaired Renal Function].
    Funaguchi N; Nakajima Y; Kaito D; Yanase K; Ito F; Endo J; Morishita M; Asano M; Iihara H; Mori H; Ohno Y; Minatoguchi S
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):705-8. PubMed ID: 26199241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
    Karampeazis A; Voutsina A; Souglakos J; Kentepozidis N; Giassas S; Christofillakis C; Kotsakis A; Papakotoulas P; Rapti A; Agelidou M; Agelaki S; Vamvakas L; Samonis G; Mavroudis D; Georgoulias V
    Cancer; 2013 Aug; 119(15):2754-64. PubMed ID: 23661337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management and maintenance of pemetrexed monotherapy regimen - initial experience of pretreated non-small cell lung cancer].
    Takase M; Maruoka H; Ametani F; Takahashi M; Shibata K
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):563-5. PubMed ID: 22504678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Safety of pemetrexed mono-therapy in elderly patients with non-small cell lung cancer].
    Konishi A; Kitada N; Nanjo S; Tanaka S; Tomii K; Katakami N; Hashida T
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1507-10. PubMed ID: 23064061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Di BS; Wei KP; Tian JH; Xiao XJ; Li Y; Zhang XH; Yu Q; Yang KH; Ge L; Huang WH; Zhang FW
    Asian Pac J Cancer Prev; 2014; 15(8):3419-24. PubMed ID: 24870732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
    Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
    Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.
    Chung FT; Lee KY; Fang YF; Shieh MH; Lin SM; Yu CT; Lo YL; Lin TY; Kuo CH; Feng PH; Ni YL; Kuo HP
    Chemotherapy; 2011; 57(2):147-55. PubMed ID: 21454972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
    Zukin M; Barrios CH; Pereira JR; Ribeiro Rde A; Beato CA; do Nascimento YN; Murad A; Franke FA; Precivale M; Araujo LH; Baldotto CS; Vieira FM; Small IA; Ferreira CG; Lilenbaum RC
    J Clin Oncol; 2013 Aug; 31(23):2849-53. PubMed ID: 23775961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
    Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
    Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pemetrexed as second-line treatment and beyond for elderly patients with advanced non-small-cell lung cancer].
    Otani S; Igawa S; Maki S; Nagashima Y; Hayashi N; Kimura M; Ishihara M; Kasajima S; Hiyoshi Y; Katono K; Takakura A; Mitsufuji H; Katagiri M; Kubota M; Masuda N
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):59-62. PubMed ID: 22241352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The efficacy and safety of pemetrexed as monotherapy for Chinese patients with advanced non-small cell lung cancer].
    Zhong W; Zhao J; Zhang XT; Zhang L; Wang MZ; Li LY
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):671-4. PubMed ID: 20979786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.